Skip to content

Glucose tolerance evaluation by continuous glucose monitoring (CGM) after gestational diabetes

Glucose tolerance evaluation by continuous glucose monitoring (CGM) after gestational diabetes - Glucose tolerance evaluation by CGM after GDM

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000034547
Enrollment
20
Registered
2018-10-31
Start date
2018-11-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational Diabetes Mellitus

Interventions

Postpartum patients of Gestational diabetes attach CGM between 7 to 14 days.The patient takes a test meal one day during wearing. Healthy postpartum women are control group and attach CGM between 7 to

Sponsors

Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: GDM group:Women who gave birth at University Hospital Kyoto Prefectural University of Medicine or Adachi Hospital.And those who have been diagnosed with gestational diabetes during pregnancy and are over 6 months and within 3 years after birth and after resuming menstruation,who are not pregnant or lactating. Patients who gave birth at Adachi Hospital are introducted to University Hospital Kyoto Prefectural University of Medicine when after birth examination. non-GDM group:Women who did not diagnosed gestational diabetes during pregnancy and are over 6 months and within 3 years after birth and after resuming menstruation, who are not pregnant or lactating. We do not limit hospitals they gave birth.

Exclusion criteria

Exclusion criteria: We exclude patients who have been diagnosed as borderline type diabetes or diabetes type after childbirth and obvious diabetes mellitus during pregnancy and pregnancy with diabetes mellitus. Patients who the doctor judged inappropriate for participation in the trial, patients who declared non-acceptance of participation are excluded.

Design outcomes

Primary

MeasureTime frame
Differences in blood glucose fluctuation between 7 and 14 days in GDM group and non-GDM group.

Secondary

MeasureTime frame
Evaluate the difference such as HbA1c, glycoalbumin and Continuous overlapping net Glycemic Action (CONGA), SD, Mean, Max, Min and J-index in CGM data, between GDM group and non-GDM group.

Countries

Japan

Contacts

Public ContactAya Kitae

Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan Department of Endocrinology and Metabolism

kitaeaya@koto.kpu-m.ac.jp075-252-5506

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026